New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSyn-Coll vs Orforglipron

Syn-Coll vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Syn-Coll
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
Extended (lipid depot in stratum corneum)
~12 hours (once-daily oral dosing)
Admin Route
Topical
Oral
Research
Typical Dose
0.005-0.05% in formulation
12 mg → 24 mg → 36 mg → 45 mg
Frequency
Once or twice daily
Once daily
Key Benefits
  • Directly activates TGF-beta for potent collagen synthesis stimulation
  • Increases dermal thickness and firmness
  • Reduces depth of wrinkles and fine lines
  • Improves skin elasticity
  • Clinically validated in collagen induction studies
  • Complementary to retinoids or vitamin C
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Generally well-tolerated
  • Rare mild irritation at high concentrations
  • Possible sensitivity in individuals with inflammatory skin conditions
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With